IGC Pharma Inc. (NYSE: IGC), which was formerly known as India Globalization Capital, announced Wednesday it plans to advance its drug candidate IGC-AD1 into clinical trials as a potential anti-amyloid treatment for Alzheimer’s disease. The move follows recent FDA approvals of anti-amyloid drugs from Eli Lilly and Eisai/Biogen, signaling growing …
… New Jersey. Separately, Marijuana Moment reported in April that the Justice Department was investigating marijuana-related businesses that …
… Cannabis · Advice · Travel · Pets and Animals · Comics · Puzzles and Games … Hiker found dead after going missing in Sierra Nevada. Other remains …
Nearly 40 years ago, advocates made the case to the DEA’s own judge that cannabis did not meet the definition of a Schedule I controlled substance. Their case is exponentially stronger now. The post NORML Op-Ed: DEA’s Marijuana Hearing Is a Good Opportunity for Advocates To Make the Case for Rescheduling appeared first on NORML.